Whole genome sequencing solution


Life Sciences

Anzu Investment:

August 2019


ResolveDNA™, powered by PTA, provides superior whole genome amplification (WGA) performance metrics in single cells compared to all current methods

BioSkryb has ushered in a whole new era of single-cell whole genome amplification. The benefits of the BioSkryb ResolveDNA™ technology include the ability to control the amplicon size during amplification. This allows the incorporation of barcode identifiers into each sample template, enabling unparalleled reproducibility and sensitive detection of DNA lesions.

Primary Template-directed Amplification (PTA) is a novel, more accurate, whole genome amplification (WGA) approach for single cells or ultra-low DNA input samples. The PTA platform elevates single cell genome variant calling metrics to a new gold standard compared to current methodologies. 

BioSkryb’s complete workflow solution is especially useful in cancer research as it allows the detection of single resistant mutant cells (MRD) in heterogeneous cancers such as leukemia. It also enables new applications for gene sequencing that need a level of resolution simply not available today.

Interested in more information?

Complete the form below to get connected directly with the portfolio company